Actemra gets advisory committee review
Executive Summary
Roche's Actemra (tocilizumab) will be evaluated by FDA's Arthritis Drugs Advisory Committee July 29. The rheumatoid arthritis candidate has a September user fee date, and if approved would be the first interleukin-6 receptor inhibitor approved for treatment of moderately to severely active rheumatoid arthritis in adults. Roche is seeking approval as monotherapy and in combination with disease-altering antirheumatic drugs
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.